Nichi-Iko Pharmaceutical Co., Ltd. provided consolidated earnings guidance for the year ending March 31, 2021. For the year, the company expected revenue of ¥199,000 million, operating profit of ¥7,500 million, profit attributable to owners of parent of ¥5,200 million or ¥81.25 basic earnings per share.